Regenxbio (RGNX) Releases Earnings Results, Misses Estimates By $0.93 EPS

Regenxbio (NASDAQ:RGNX) posted its earnings results on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.93), Bloomberg Earnings reports. Regenxbio had a net margin of 37.28% and a return on equity of 23.27%. The business had revenue of $40.03 million during the quarter, compared to analysts’ expectations of $100.00 million.

NASDAQ RGNX traded up $0.70 on Friday, hitting $67.40. 2,050,400 shares of the stock were exchanged, compared to its average volume of 552,838. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -26.43, a PEG ratio of 1.83 and a beta of -1.16. Regenxbio has a 52-week low of $19.45 and a 52-week high of $85.10.

Several research analysts have commented on the stock. BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 1st. Raymond James set a $45.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Chardan Capital lifted their price objective on shares of Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, July 16th. TheStreet raised shares of Regenxbio from a “d+” rating to a “c” rating in a research note on Friday, May 11th. Finally, Barclays reaffirmed an “overweight” rating and set a $48.00 price objective (up from $38.00) on shares of Regenxbio in a research note on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Regenxbio has an average rating of “Buy” and a consensus price target of $64.19.

In other Regenxbio news, insider Kenneth T. Mills sold 10,000 shares of Regenxbio stock in a transaction on Monday, May 21st. The shares were sold at an average price of $47.05, for a total transaction of $470,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Patrick J. Christmas sold 5,000 shares of Regenxbio stock in a transaction on Monday, June 18th. The stock was sold at an average price of $56.78, for a total transaction of $283,900.00. Following the transaction, the senior vice president now directly owns 21,141 shares of the company’s stock, valued at $1,200,385.98. The disclosure for this sale can be found here. Insiders have sold 72,600 shares of company stock valued at $4,033,675 over the last ninety days. 16.90% of the stock is owned by insiders.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Further Reading: What is a Leveraged Buyout (LBO)?

Earnings History for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply